Development of Severe Hypophosphatemia from Acquired Fanconi Syndrome during Treatment with Abiraterone
Journal Title: Journal of Case Reports and Studies - Year 2015, Vol 3, Issue 1
Abstract
Objectives: To report two cases of patients with metastatic, castration resistant prostate cancer who developed profound hypophosphatemia while on treatment with abiraterone. Case Summary: The first patient was a 77 year old man who had been on abiraterone for 12 months before his phosphorous was checked. At that point, it was 0.6 mg/dl, which is severely decreased. A full work up for hypophosphatemia showed normal parathyroid hormone and 25-hydroxyvitamin D. A urine study showed inappropriate excretion of phosphorous along with aminoaciduria and normoglycemic glucosuria. The phosphorous level slowly improved upon discontinuation of abiraterone and aggressive repletion of his phosphorous with elemental phosphorous and calcitriol. The second patient was a 74 year old man who had a slightly decreased phosphorous prior to abiraterone initiation. It steadily fell during abiraterone therapy down to 0.9 mg/dl. Aggressive repletion would not raise the phosphorous to normal. It only improved upon discontinuation of abiraterone. The results of the work up were similar to those of the first patient. Discussion: These two patients had profound hypophosphatemia. Phosphorous levels are not routinely checked by clinicians, and the severe hypophosphatemia in these patients demonstrates how important it is to check this level. We propose that the mechanism of phosphorous loss is through inappropriate renal wasting by Fanconi syndrome. Conclusion: Hypophosphatemia occurs in prostate cancer patients on abiraterone. It should be monitored closely in patients on this therapy.
Authors and Affiliations
Graff JN
Keywords
Related Articles
- EP ID EP582827
- DOI 10.15744/2348-9820.2.401
- Views 87
- Downloads 0
Cisplatin-Gemcitabine Related Cardiomyopathy in Non-Small Cell Lung Cancer NSCLC Patient: A Case Study
Gemcitabine is a pyrimidine analog and cisplatin is a platinum agent, they are usually combined to form a chemotherapeutic doublet used to treat different types of oncological cancers, including non-small cell lung cance...
Primary Cutaneous Hodgkin Lymphoma: A Rare Disease Variant and Review of the Literature
A 49-year-old man presented with a 2-year history of an enlarging ulcerated plaque over the right forearm with an associated history of pruritus. Skin biopsy demonstrated an infiltrate of lymphocytes in the dermis and su...
Acquired Factor XII Deficiency in a Patient with Schizophrenia
We report a 50-year-old man who presented schizophrenia and an abnormal coagulation profile indicative of an inhibitor. Clinical experiments demonstrated prolonged partial thromboplastin time along with acquired factor X...
Spinal Cord Compression Due to Extramedullary Hematopoiesis in a 27-YearOld Man with Beta Thalassemia Intermedia: A Case Report
Background: Extramedullary hematopoiesis (EMH) occurs in approximately 15% of cases of thalassemia. Paraspinal mass of extramedullary hematopoiesis are a rare compensatory process in intermediate and severe thalassemia....
Hepatic Angiosarcoma, going but not gone. Lessons from a single centre experience
Hepatic angiosarcoma is a rare tumour that is often difficult to diagnose. Historically, most cases of hepatic angiosarcoma were seen in the setting of industrial epidemics caused by exposure of workers to toxins such as...